miércoles, 7 de octubre de 2026
BuscarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 9, 2026

Stock market today: Nasdaq turns positive, Dow, S&P 500 slip as oil prices ease after spiking above $100

View original at finance.yahoo.com
Stock market today: Nasdaq turns positive, Dow, S&P 500 slip as oil prices ease after spiking above $100 US stocks trimmed heavy losses on Monday as crude prices eased after they surged past $100 per barrel amid fears of a prolonged Middle East conflict…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Investors appear to be selling their winning longs and buying back one of their biggest shorts, software

    80% confidence
  • Lamb Weston should expand the cost reduction program and conduct strategic review of certain international operations, particularly in Asia Pacific

    80% confidence
  • If banks cannot catch a bid on a steeper curve, that is the warning

    80% confidence
  • The market is trading financials like a credit-stress proxy despite friendlier yield curve

    80% confidence
  • When WTI trades in parity to Brent, it's a clear sign the global oil market is under an immense amount of stress

    80% confidence
  • The impact of higher fuel costs on airfare would 'probably start quick'

    80% confidence
  • The Iran situation could lead the US into a recession

    80% confidence
  • This looks more like a short-covering bounce than the start of a durable software comeback

    80% confidence
  • Lamb Weston is well positioned to enter a new phase of value creation defined by structural improvement in margins, capital allocation, and earnings power

    80% confidence
  • G7 agreed on following the oil situation very closely and are ready to take all necessary measures, including using strategic reserves to stabilize the market

    80% confidence
  • High oil costs were 'a very small price to pay' for security

    80% confidence
  • Iranian military commander said oil would hit $200 per barrel if airstrikes on the country's infrastructure didn't stop

    80% confidence
  • Hims had an agreement that mass compounding would stop and unfortunately it didn't stop, which is why Novo ended the first partnership

    80% confidence
  • An additional $250 million in cost cuts is necessary beyond the initial $250 million program

    80% confidence

Data points we hold from this source

Novo Nordisk A/S · daily return1 percent
Dow Jones Industrial Average · daily return-0.7 percent
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
Nuestra lectura de los datos ›
Señales que seguimos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,986
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,986 hechos verificados con la fuente5,362 documentos fuente archivados
Consulta estos datos → isubstrate.com